In summary, this study suggests that the synthesized MAP vaccine based on B-cell epitopes of human HPSE is capable of attenuating human HCC metastasis in vivo, which is probably induced by suppressing HPSE activity [18], [21] and tumor associated angiogenesis, by virtue of the anti-MAP polyclonal antibodies. This evidence concerns the gene HPSE and hepatocellular carcinoma.